Gardasil Related Published Studies
Well-designed clinical trials related to Gardasil (Human Papillomavirus Vaccine)
Mother-infant transfer of anti-human papillomavirus (HPV) antibodies following
vaccination with the quadrivalent HPV (type 6/11/16/18) virus-like particle
vaccine. [2012]
Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine. [2011.03.15]
The accuracy of colposcopic biopsy: analyses from the placebo arm of the Gardasil clinical trials. [2011.03.15]
Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial. [2011.03]
Quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine: for the
prevention of genital warts in males. [2011]
The accuracy of colposcopic biopsy: analyses from the placebo arm of the Gardasil
clinical trials. [2011]
Prevalence and type distribution of human papillomavirus in healthy Japanese
women aged 20 to 25 years old enrolled in a clinical study. [2011]
Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. [2010.10]
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. [2010.07.20]
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. [2010.07.20]
Safety, tolerability, and immunogenicity of gardasil given concomitantly with Menactra and Adacel. [2010.06]
An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age. [2010.04]
Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine. [2010.02]
Efficacy of human papillomavirus type 16/18 AS04-adjuvanted vaccine in Japanese
women aged 20 to 25 years: final analysis of a phase 2 double-blind, randomized
controlled trial. [2010]
Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. [2009.12]
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. [2009.06.06]
Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE Study Economic Evaluation. [2008.12]
Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women. [2008.03]
Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. [2007.07]
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. [2007.05.10]
Well-designed clinical trials possibly related to Gardasil (Human Papillomavirus Vaccine)
Development and application of a GuHCl-modified ELISA to measure the avidity of
anti-HPV L1 VLP antibodies in vaccinated individuals. [2012]
Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial. [2011.04.13]
Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. [2011.02.03]
Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. [2011]
Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA
expressing antigenic regions of HPV 16 and 18 results in an increase in the
precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and
11. [2011]
Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to
cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection. [2011]
Characterization of the HPV-specific memory B cell and systemic antibody
responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine. [2010]
The efficacy of HPV 16/18 vaccines on sexually active 18-23 year old women and the impact of HPV vaccination on organized cervical cancer screening. [2009]
Behavioral frequency moderates the effects of message framing on HPV vaccine acceptability. [2008.04]
Other research related to Gardasil (Human Papillomavirus Vaccine)
Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent
Finnish females 4 years post-vaccination. [2012]
Safety and immunogenicity of a vaccine targeting human papillomavirus types 6,
11, 16 and 18: a randomized, double-blind, placebo-controlled trial in Chinese
males and females. [2012]
Evidence of immune memory 8.5 years following administration of a prophylactic
human papillomavirus type 16 vaccine. [2012]
Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine
in males 16 to 26 years old. [2012]
Vaccine-relevant human papillomavirus (HPV) infections and future acquisition of
high-risk HPV types in men. [2012]
How to inform: comparing written and video education interventions to increase
human papillomavirus knowledge and vaccination intentions in young adults. [2012]
The cost effectiveness of human papillomavirus vaccines: a systematic review. [2012]
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: Follow-up from Months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. [2011.12.01]
[Diseases caused by human papilloma viruses]. [2011.05]
[Human papillomavirus infection and adolescence]. [2011.04]
The knowledge levels and opinions of biomedical students regarding the human papillomavirus quadrivalent (types 6, 11, 16, and 18) recombinant vaccine. [2011.04]
Quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine: for the prevention of genital warts in males. [2011.03.26]
Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer. [2011.03]
Advances in human papilloma virus vaccines: a patent review. [2011.03]
Prevalence and genotype characterization of human papillomaviruses among HIV-seropositive in Ouagadougou, Burkina Faso. [2011.03]
Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics. [2011.02]
Guillain-Barre syndrome after Gardasil vaccination: data from Vaccine Adverse Event Reporting System 2006-2009. [2011.01.29]
[Vaccination against human papilloma virus and cervical cancer]. [2011.01]
Postlicensure safety evaluation of human papilloma virus vaccines. [2011]
Papillomavirus virus like particle-based therapeutic vaccine against human papillomavirus infection related diseases: immunological problems and future directions. [2011]
Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil(R)): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women. [2010.12.24]
Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine. [2010.11.29]
Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model. [2010.10.18]
Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. [2010.10.15]
A brief history of economic evaluation for human papillomavirus vaccination policy. [2010.09]
Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance. [2010.09]
Low rates of free human papillomavirus vaccine uptake among young women. [2010.09]
A case study: lessons learned from human papillomavirus vaccine development: approval of a vaccine for use in children and young adolescents for prevention of an adult disease. [2010.07.01]
Measuring serum antibody to human papillomavirus following infection or vaccination. [2010.06]
Who's guarding what? A poststructural feminist analysis of gardasil discourses. [2010.03]
Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus. [2010.03]
Development of a novel viral DNA vaccine against human papillomavirus: AcHERV-HP16L1. [2010.02.10]
Acceptability of human papillomavirus vaccine for males: a review of the literature. [2010.02]
Predictors of parents' willingness to vaccinate for human papillomavirus and physicians' intentions to recommend the vaccine. [2010.01]
Erythema multiforme following vaccination for human papillomavirus. [2010]
Why consider human papillomavirus vaccination in older women? [2010]
Human papilloma virus vaccination in Nepal: an initial experience in Nepal. [2010]
The quadrivalent human papillomavirus vaccine: erythema multiforme and cutaneous side effects after administration. [2010]
An open-label, randomized, multicenter study of the safety, tolerability, and
immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine
given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis
vaccine in healthy adolescents 11 to 17 years of age. [2010]
Clinical trial and post-licensure safety profile of a prophylactic human
papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine. [2010]
Barriers for Hispanic women in receiving the human papillomavirus vaccine: a nursing challenge. [2009.12]
Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. [2009.12]
Antibody responses in oral fluid after administration of prophylactic human papillomavirus vaccines. [2009.11.01]
Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix. [2009.11]
Allaying parental concerns about the human papillomavirus vaccine. [2009.11]
Distribution of human papillomavirus types in cervical cancers in Hong Kong: current situation and changes over the last decades. [2009.10.01]
Efficacy of human papillomavirus vaccines: a systematic quantitative review. [2009.10]
Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. [2009.10]
The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24. [2009.10]
Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. [2009.08.19]
Quadrivalent Human Papillomavirus recombinant vaccine associated lipoatrophy. [2009.08.06]
Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia. [2009.08]
Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. [2009.06.03]
Worldwide impact of the human papillomavirus vaccine. [2009.04]
The case for vaccinating boys against human papillomavirus. [2009]
Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health. [2009]
Other possibly related research studies
Long-term follow-up in cancer prevention trials (It ain't over 'til it's over). [2010.06]
HPV vaccines: state of the art. [2010.09]
HPV vaccination coverage among adolescents aged 9 to 17 years in a United States military treatment facility. [2009.10]
Currently approved prophylactic HPV vaccines. [2009.12]
Current prophylactic HPV vaccines and gynecologic premalignancies. [2009.12]
Papillomavirus prophylactic vaccines: established successes, new approaches. [2010.02]
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. [2009.10]
Impact of a quadrivalent HPV6/11/16/18 vaccine in Mexican women: public health implications for the region. [2009.08]
Advantages and disadvantages of current prophylactic vaccines against HPV. [2009.08]
Anal condyloma acuminatum. [2009.09]
Attitudes, knowledge, and practices in relation to cervical cancer and its screening among women in Saudi Arabia. [2009.09]
Obstetrician-gynecologists and the HPV vaccine: practice patterns, beliefs, and knowledge. [2009.08]
Hear all about it: nightly television news coverage of cervical cancer vaccination in the United States. [2009.07]
The HPV vaccines--which to prefer? [2009.05]
Is male intent to be vaccinated against HPV a function of the promotion message? [2011.06]
Reducing the rate of cervical cancer: ethical challenges in public health. [2010.12]
|
